Cancer Biological Therapy Market Trends, Opportunities & Competitive Landscape
The growing adoption of biologic medicines in oncology is creating new opportunities across the Cancer Biological Therapy Market. Market revenue reached USD 84.62 billion in 2024, up from USD 81 billion in 2023, and is forecast to increase to USD 120 billion by 2032. The report estimates a CAGR of 4.47% from 2025 to 2032. Rising cancer prevalence, expanding clinical trial activity, and increased funding for pharmaceutical research are encouraging the development of advanced therapies. The shift toward targeted treatments and personalized medicine is also influencing how pharmaceutical companies design and evaluate new biological products.
The market is organized around five major therapy types: monoclonal antibodies, cancer vaccines, cytokines, gene therapy, and cell therapy. It also covers several cancer indications and routes of administration, including intravenous, subcutaneous, oral, intramuscular, and topical delivery. Intravenous administration is prominent, while subcutaneous and oral options offer alternative approaches to treatment delivery. Hospitals are major end users, supported by specialty clinics, research institutes, and pharmaceutical companies. North America holds the largest regional share, followed by Europe and Asia-Pacific. Growth opportunities include combination therapies, immune-oncology research, targeted treatments for specific cancers, and greater investment in personalized medicine. Companies profiled in the report include Roche, Gilead Sciences, Pfizer, Takeda Pharmaceuticals, Novartis, Bristol Myers Squibb, Regeneron Pharmaceuticals, Merck, Sanofi, and AstraZeneca.
FAQs
-
What is the expected market growth rate?
The report estimates a CAGR of 4.47% for 2025–2032. -
Which therapy types are included in the market?
Monoclonal antibodies, cancer vaccines, cytokines, gene therapy, and cell therapy. -
Why is personalized medicine important to this market?
It supports treatment selection based on individual patient and tumor characteristics. -
Which region has the second-largest market value?
Europe is the second-largest regional market, valued at USD 24 billion in 2024. -
What opportunities are emerging for market participants?
Targeted therapies, combination treatments, immune-oncology, and research investment offer significant opportunities.
- Art
- Causes
- Crafts
- Dance
- Drinks
- Film
- Fitness
- Food
- Juegos
- Gardening
- Health
- Home
- Literature
- Music
- Networking
- Other
- Party
- Religion
- Shopping
- Sports
- Theater
- Wellness